- Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Clinical pharmacology in drug development (2017-03-17)
Susanne Johansson, David P Rosenbaum, Marie Ahlqvist, Helen Rollison, Mikael Knutsson, Bergur Stefansson, Marie Elebring
PMID28301096
ABSTRACT
Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger isoform 3 in development for the treatment of constipation-predominant irritable bowel syndrome and the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. We aimed to investigate whether tenapanor inhibits or induces cytochrome P450s (CYPs). In vitro experiments assessing the potential of tenapanor to affect various CYPs indicated that it could inhibit CYP3A4/5 (IC
MATERIALI